Direct-to-Patient Drug Funding via Tokens

Replace manual claims processing with an immutable, shared ledger. Every dollar of drug funding is tokenized and tracked from manufacturer to patient, creating a perfect audit trail.

• Automated KYC/AML checks ensure funds reach verified, eligible patients.
• Smart contracts enforce program rules, preventing duplicate claims and off-label use.
• Real-time transparency for regulators reduces audit preparation from weeks to hours, as seen in pilot programs with specialty pharmacies.

Automate manual reconciliation between manufacturers, foundations, and pharmacies. Smart contracts auto-distribute funds upon verified prescription fulfillment, eliminating invoicing delays and manual data entry.

• Example: A mid-sized biotech reduced its PAP (Patient Assistance Program) admin team from 12 FTEs to 4, reallocating $500k annually to R&D.
• Interoperable tokens work across pharmacy networks, removing the need for custom integrations and reducing IT support costs.

Reduce the time from prescription to therapy initiation from weeks to days. Digital tokens enable instant eligibility verification and co-pay settlement at the point of prescription.

• Faster access leads to better adherence and health outcomes, directly impacting drug efficacy data.
• Real-world evidence (RWE) collection is streamlined via patient-consented data attached to token transactions, providing invaluable insights for market access strategies.

Tokenized programs generate granular, compliant data flows. This enables performance-based contracting with payers and dynamic pricing models.

• Proof-of-Outcome: Tie rebates or funding releases to verified patient adherence data captured on-chain.
• Market Expansion: Use de-identified RWE from token interactions to demonstrate value in new patient populations, supporting label expansions.

A typical enterprise implementation shows payback in <18 months. The ROI calculation is clear:

• Cost Reduction: 60-80% lower administrative costs for PAPs and co-pay programs.
• Revenue Protection: Near-elimination of fraud and program abuse.
• Capital Efficiency: Reduced need for working capital tied up in slow reimbursement cycles.
• Strategic Value: Enhanced data asset and improved market access capabilities.

Replace opaque, fraud-prone paper-based systems with tokenized assistance vouchers. Each voucher is a non-transferable token issued directly to a verified patient's digital wallet, redeemable only at approved pharmacies. This ensures funds are used as intended.

• Cost Savings: Reduces administrative fraud and manual processing costs by an estimated 40%.
• Patient Experience: Instant verification at point-of-sale, eliminating claim forms and wait times.
• Audit Trail: Pharma manufacturers gain real-time, granular data on program utilization and patient reach.

Securitize future patient reimbursement streams (e.g., from insurers or national health services) into tradable bond tokens. This provides healthcare providers with immediate working capital instead of waiting 90+ days for payments, dramatically improving cash flow.

• Financial ROI: Unlocks capital at lower cost than traditional factoring (rates reduced by 200-300 basis points).
• Risk Mitigation: Payment triggers are automated via smart contracts upon verification of treatment delivery.
• Example: Early pilots in European healthcare systems are exploring this to fund advanced therapy access.

The immutable ledger provides a single source of truth for all transactions, from donor to patient to provider. This is not just a technical feature; it's a core business benefit for regulated industries.

• Automated Reporting: Generate compliance reports for HIPAA, GDPR, and financial regulators in minutes, not weeks.
• Fraud Reduction: Near-elimination of duplicate billing or fraudulent claims due to transparent fund trails.
• CIO Justification: Reduces legal and audit preparation costs by up to 50%, while providing irrefutable proof of fund stewardship.

Replace manual grant administration and paper-based verification with smart contract automation. Funds are released only when predefined clinical or treatment milestones are verified on-chain, slashing administrative overhead by up to 60%. This directly addresses the $3-5B in annual fraud and waste estimated in traditional patient assistance programs. Real-world pilots, like those in oncology support, have shown a 90% reduction in payment processing time and near-zero reconciliation errors.

Tokenize patient assistance funds to create a liquid, programmable asset class. This allows:

• Philanthropic donors and impact investors to fund specific patient cohorts with full transparency.
• Pharma manufacturers to create targeted, compliant co-pay programs that directly reach patients.
• Real-time audit trails that satisfy regulatory scrutiny (e.g., OIG, Anti-Kickback Statute compliance). Example: A pilot for a rare disease drug used tokenized vouchers, increasing patient enrollment by 40% by simplifying the application and verification burden on clinics.

Every transaction—from donor contribution to final patient payment—is immutably recorded. This creates an automated compliance engine that:

• Proves fund usage aligns with donor intent and program rules.
• Generates real-time reports for regulators, reducing audit preparation from weeks to hours.
• Ensures data privacy via zero-knowledge proofs, where necessary, to share proof of compliance without exposing sensitive patient data. This turns a major cost center (compliance overhead) into a defensible, automated asset.

With patient consent, tokenized interactions create a verifiable data layer for outcomes-based research. This enables:

• Longitudinal treatment adherence tracking linked to funding, providing real-world evidence (RWE) for payers and researchers.
• Secure, patient-controlled data sharing with academic institutions for clinical studies.
• Dynamic funding models where future assistance can be tailored based on anonymized, aggregated outcomes data. This transforms patient support from a cost into a strategic data asset, potentially unlocking new value-based contracting models.

A successful 6-month pilot focuses on a single therapeutic area with a clear ROI dashboard. Key milestones include:

• Phase 1 (Months 1-2): Design tokenomics and smart contracts for a specific drug co-pay program. Integrate with one clinic's EHR system via API.
• Phase 2 (Months 3-4): Onboard 50-100 patients. Measure key metrics: time-to-funding, admin hours saved, patient satisfaction.
• Phase 3 (Months 5-6): Scale to 3-5 clinics. Finalize ROI analysis targeting 25-30% operational cost reduction and a >20% increase in patient adherence due to reduced financial toxicity. This phased approach de-risks investment and delivers tangible proof points for a full-scale rollout.

Leverage enterprise-grade, modular components for a low-friction pilot:

• Private, Permissioned Ledger: For controlled access and regulatory compliance (e.g., Hyperledger Fabric, Corda).
• Smart Contract Oracles: To securely pull verified data from external systems (EHRs, pharmacy claims).
• Non-Custodial Wallets: Allow patients to hold and use tokenized benefits without managing crypto directly.
• Existing ERP/CRM Integration: Plug into SAP, Salesforce, or custom portals via standard APIs. The goal is interoperability, not rip-and-replace, ensuring the pilot complements existing IT investments.